How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
Hematol., Transfus. Cell Ther. (Impr.)
; 42(2): 103-110, Apr.-June 2020. ilus
Artigo
em Inglês
| LILACS
| ID: biblio-1134022
Biblioteca responsável:
BR408.1
Localização: BR408.1
ABSTRACT
ABSTRACT The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Leucemia Linfoide
/
Coronavirus
/
COVID-19
/
Linfoma
País/Região como assunto:
América do Sul
/
Brasil
Idioma:
Inglês
Revista:
Hematol., Transfus. Cell Ther. (Impr.)
Assunto da revista:
Hematologia
/
TransfusÆo de Sangue
Ano de publicação:
2020
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
AC Camargo Cancer Center/BR
/
Américas Oncologia/BR
/
CEON+BR
/
Centro de Cancer de Brasilia CETTRO/BR
/
Hospital Alemão Oswaldo Cruz/BR
/
Hospital Israelita Albert Einstein/BR
/
Hospital das Clínicas/BR
/
Hospital de Clínicas de Porto Alegre/BR
/
Instituto Nacional do Cancer - INCA/BR
/
Instituto do Cancer de São Paulo/BR
